{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:47:18Z","timestamp":1790765238036,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012836","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:00:00Z","timestamp":1553040000000}}],"reference-count":184,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012836.pub2","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T14:02:28Z","timestamp":1553090548000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Linezolid for drug-resistant pulmonary tuberculosis"],"prefix":"10.1002","author":[{"given":"Bhagteshwar","family":"Singh","sequence":"first","affiliation":[{"name":"Royal Liverpool University Hospital; Tropical and Infectious Diseases Unit; Liverpool UK"},{"name":"University of Liverpool; Institute of Infection & Global Health; Liverpool UK"},{"name":"Liverpool School of Tropical Medicine; Department of Clinical Sciences; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Cocker","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine; Department of Clinical Sciences; Liverpool UK"},{"name":"Northwick Park Hospital; Watford Road Harrow Middlesex UK HA1 3UJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Ryan","sequence":"additional","affiliation":[{"name":"Royal Liverpool University Hospital; Tropical and Infectious Diseases Unit; Liverpool UK"},{"name":"Liverpool School of Tropical Medicine; Department of Clinical Sciences; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J","family":"Sloan","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine; Department of Clinical Sciences; Liverpool UK"},{"name":"University of St Andrews; School of Medicine; North Haugh St Andrews UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,20]]},"reference":[{"key":"10.1002\/14651858.CD012836.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/S1473-3099(18)30100-2","article-title":"Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study","volume":"18","author":"Ferlazzo","year":"2018","journal-title":"Lancet Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD012836.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3390\/ijms17060960","article-title":"Pediatric tuberculosis in Italian children: epidemiological and clinical data from the Italian register of pediatric tuberculosis","volume":"17","author":"Galli","year":"2016","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"1601799","DOI":"10.1183\/13993003.01799-2016","article-title":"Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis","volume":"49","author":"Guglielmetti","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD012836.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"786","DOI":"10.5588\/ijtld.15.0895","article-title":"Multidrug-resistant tuberculosis in Norway: a nationwide study, 1995-2014","volume":"20","author":"Jensenius","year":"2016","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"11","key":"10.1002\/14651858.CD012836.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1093\/jac\/dkv215","article-title":"Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment","volume":"70","author":"Jeong","year":"2015","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5588\/ijtld.13.0307","article-title":"Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis","volume":"18","author":"Jo","year":"2014","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"5","key":"10.1002\/14651858.CD012836.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.5588\/ijtld.14.0739","article-title":"Changes in treatment outcomes of multidrug-resistant tuberculosis","volume":"19","author":"Kwak","year":"2015","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"3","key":"10.1002\/14651858.CD012836.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1056\/NEJMc1500286","article-title":"Linezolid for XDR-TB - final study outcomes","volume":"373","author":"Lee","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"10.1002\/14651858.CD012836.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012836.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1183\/09031936.00009509","article-title":"A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis","volume":"34","author":"Migliori","year":"2009","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"1800544","DOI":"10.1183\/13993003.00544-2018","article-title":"Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa","volume":"51","author":"Olayanju","year":"2018","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Padayatchi N Mac Kenzie WR Hirsch-Moverman Y Feng PJ Villarino E Saukkonen J Lessons from a randomised clinical trial for multidrug-resistant tuberculosis International Journal of Tuberculosis and Lung Disease 2012 1582 7","DOI":"10.5588\/ijtld.12.0315"},{"issue":"5","key":"10.1002\/14651858.CD012836.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/thoraxjnl-2013-203900","article-title":"High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study","volume":"69","author":"Seddon","year":"2014","journal-title":"Thorax"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1183\/09031936.00035114","article-title":"Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China","volume":"45","author":"Tang","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD012836.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1183\/13993003.02146-2015","article-title":"Effectiveness and safety of meropenem\/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB","volume":"47","author":"Tiberi","year":"2016","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD012836.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1183\/13993003.00214-2016","article-title":"Comparison of effectiveness and safety of imipenem\/clavulanate-versus meropenem\/clavulanate-containing regimens in the treatment of MDR- and XDR-TB","volume":"47","author":"Tiberi","year":"2016","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD012836.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"936-8; author r","DOI":"10.1183\/09031936.00132009","article-title":"Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective","volume":"35","author":"Udwadia","year":"2010","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD012836.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"406","DOI":"10.5588\/ijtld.14.0838","article-title":"Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000-2009","volume":"19","author":"Altena","year":"2015","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"4","key":"10.1002\/14651858.CD012836.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s15010-014-0632-2","article-title":"Linezolid in the treatment of extensively drug-resistant tuberculosis","volume":"42","author":"Zhang","year":"2014","journal-title":"Infection"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0020|cit20","first-page":"19","article-title":"Tuberculosis treatment. A practical guide elaborated by the tuberculosis section, Argentine Association of Respiratory Medicine","volume":"7","author":"Abbate","year":"2007","journal-title":"Revista Argentina de Mediciina Respiratoria"},{"issue":"8","key":"10.1002\/14651858.CD012836.pub2-BIB0021|cit21","first-page":"778","article-title":"Extensively drug-resistant tuberculosis in Argentina: our experience","volume":"17","author":"Abbate","year":"2010","journal-title":"Salud i Ciencia"},{"issue":"9657","key":"10.1002\/14651858.CD012836.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"26-7; author re","DOI":"10.1016\/S0140-6736(08)61949-2","article-title":"Treatment of extensively drug-resistant tuberculosis","volume":"373","author":"Aggarwal","year":"2009","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD012836.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.5588\/ijtld.13.0182","article-title":"Monitoring changes in anti-tuberculosis treatment: associated factors determined at the time of diagnosis","volume":"17","author":"Altet","year":"2013","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"4","key":"10.1002\/14651858.CD012836.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jac\/dkq017","article-title":"Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06","volume":"65","author":"Anger","year":"2010","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD012836.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3109\/00365540903456282","article-title":"Multidrug-resistant tuberculosis: treatment outcome in Denmark, 1992-2007","volume":"42","author":"Bang","year":"2010","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD012836.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1183\/13993003.01646-2015","article-title":"Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China","volume":"47","author":"Berry","year":"2016","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD012836.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1275-6; author","DOI":"10.1183\/09031936.00200911","article-title":"Linezolid: safety and efficacy monitoring","volume":"39","author":"Bolhuis","year":"2012","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD012836.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1183\/13993003.00606-2015","article-title":"Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study","volume":"46","author":"Bolhuis","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/MD.0b013e318194757a","article-title":"Coccidioidomycosis and tuberculosis coinfection at a tuberculosis hospital: clinical features and literature review","volume":"88","author":"Cadena","year":"2009","journal-title":"Medicine"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Carroll MW Lee MS Song TS Cai Y Lee JS Lee YM Linezolid for extensively drug resistant pulmonary tuberculosis American Journal of Respiratory and Critical Care Medicine 2011 A1838","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A1838"},{"issue":"2","key":"10.1002\/14651858.CD012836.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"e57719","DOI":"10.1371\/journal.pone.0057719","article-title":"Effectiveness of a government-organized and hospital-initiated treatment for multidrug-resistant tuberculosis patients - a retrospective cohort study","volume":"8","author":"Chan","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1002\/14651858.CD012836.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S1473-3099(12)70137-8","article-title":"Linezolid for multidrug-resistant tuberculosis","volume":"12","author":"Chang","year":"2012","journal-title":"Lancet Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD012836.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1128\/AAC.00388-13","article-title":"Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?","volume":"57","author":"Chang","year":"2013","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0034|cit34","first-page":"P2818","article-title":"Linezolid in the treatment of patients with MDR TB and XDR TB","volume":"42","author":"Cherenko","year":"2013","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD012836.pub2-BIB0035|cit35","first-page":"293","article-title":"Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates","volume":"43","author":"Coban","year":"2009","journal-title":"Mikrobiyoloji Bulteni"},{"issue":"265","key":"10.1002\/14651858.CD012836.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"265ra167","DOI":"10.1126\/scitranslmed.3009500","article-title":"PET\/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis","volume":"6","author":"Coleman","year":"2014","journal-title":"Science Translational Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.7196\/samj.6455","article-title":"Prevalence and incidence of symmetrical symptomatic peripheral neuropathy in patients with multidrug-resistant TB","volume":"104","author":"Conradie","year":"2014","journal-title":"South African Medical Journal"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0038|cit38","first-page":"957","article-title":"Re-treatment of drug-resistant pulmonary tuberculosis at Battey State Hospital","volume":"90","author":"Corpe","year":"1964","journal-title":"American Review of Respiratory Disease"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S1473-3099(12)70299-2","article-title":"Linezolid for multidrug-resistant tuberculosis","volume":"13","author":"Cox","year":"2013","journal-title":"Lancet Infectious Diseases"},{"issue":"9","key":"10.1002\/14651858.CD012836.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/INF.0b013e3182154b05","article-title":"Meropenem\/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis","volume":"30","author":"Dauby","year":"2011","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"3","key":"10.1002\/14651858.CD012836.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1183\/09031936.00116011","article-title":"On linezolid efficacy and tolerability","volume":"39","author":"Lorenzo","year":"2012","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD012836.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1183\/09031936.00124312","article-title":"Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-\/XDR-TB","volume":"41","author":"Lorenzo","year":"2013","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S2213-2600(16)30433-7","article-title":"Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study","volume":"5","author":"Dheda","year":"2017","journal-title":"Lancet Respiratory Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0044|cit44","first-page":"15","article-title":"Outcome of multi-drug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic","volume":"55","author":"Dhingra","year":"2008","journal-title":"Indian Journal of Tuberculosis"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0045|cit45","doi-asserted-by":"crossref","unstructured":"Diacon AH Donald PR Pym A Grobusch M Patientia RF Mahanyele R Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance Antimicrobial Agents and Chemotherapy 2012 3271 6","DOI":"10.1128\/AAC.06126-11"},{"issue":"4","key":"10.1002\/14651858.CD012836.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijmyco.2013.09.002","article-title":"Multidrug-resistant tuberculosis treatment with linezolid-containing regimen","volume":"2","author":"Farshidpour","year":"2013","journal-title":"International Journal of Mycobacteriology"},{"issue":"2","key":"10.1002\/14651858.CD012836.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1183\/09031936.00021012","article-title":"Drug-resistant tuberculosis among foreign-born persons in Italy","volume":"40","author":"Fattorini","year":"2012","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jac\/dki148","article-title":"Linezolid for the treatment of multidrug-resistant tuberculosis","volume":"56","author":"Fortun","year":"2005","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"10","key":"10.1002\/14651858.CD012836.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1164\/rccm.2403003","article-title":"Treatment of multidrug-resistant tuberculosis: should you try this at home?","volume":"169","author":"Griffith","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012836.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3201\/eid2103.141343","article-title":"Multidrug-resistant tuberculosis in Europe, 2010-2011","volume":"21","author":"Gunther","year":"2015","journal-title":"Emerging Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD012836.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3201\/eid2203.151130","article-title":"Preliminary favorable outcome for medically and surgically managed extensively drug-resistant tuberculosis, France, 2009-2014","volume":"22","author":"Henry","year":"2016","journal-title":"Emerging Infectious Diseases"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"399","DOI":"10.5588\/ijtld.17.0741","article-title":"Treatment responses in multidrug-resistant tuberculosis in Germany","volume":"22","author":"Heyckendorf","year":"2018","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"Suppl 56","key":"10.1002\/14651858.CD012836.pub2-BIB0053|cit53","first-page":"P3327","article-title":"Use of linezolid in complex MDRTB cases","volume":"40","author":"Huang","year":"2012","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1183\/09031936.00188114","article-title":"Linezolid for multidrug-resistant tuberculosis in HIV-infected and -uninfected patients","volume":"46","author":"Hughes","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD012836.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1056\/NEJMc1214183","article-title":"Linezolid for extensively drug-resistant tuberculosis","volume":"368","author":"Jaramillo","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3201\/eid2310.161398","article-title":"Bedaquiline and linezolid for extensively drug-resistant tuberculosis in pregnant woman","volume":"23","author":"Jaspard","year":"2017","journal-title":"Emerging Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijantimicag.2013.02.019","article-title":"Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study","volume":"42","author":"Jiang","year":"2013","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0058|cit58","first-page":"529","article-title":"Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India","volume":"133","author":"Joseph","year":"2011","journal-title":"Indian Journal of Medical Research"},{"issue":"6-7","key":"10.1002\/14651858.CD012836.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3109\/00365548.2011.564649","article-title":"Linezolid in the treatment of multidrug-resistant\/extensively drug-resistant tuberculosis in paediatric patients: experience of a paediatric infectious diseases unit","volume":"43","author":"Kjollerstrom","year":"2011","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD012836.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/jac\/dkp171","article-title":"Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis","volume":"64","author":"Koh","year":"2009","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD012836.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/jac\/dkp276","article-title":"Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis - Authors' response","volume":"64","author":"Koh","year":"2009","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD012836.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/jac\/dkp344","article-title":"Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response","volume":"64","author":"Koh","year":"2009","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"6","key":"10.1002\/14651858.CD012836.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/jac\/dks078","article-title":"Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients","volume":"67","author":"Koh","year":"2012","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"7","key":"10.1002\/14651858.CD012836.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1086\/591702","article-title":"Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan","volume":"47","author":"Lai","year":"2008","journal-title":"Clinical Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD012836.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"610","DOI":"10.5588\/ijtld.11.0544","article-title":"Treatment of multidrug-resistant tuberculosis in a high-prevalence region through a binational consortium","volume":"16","author":"Laniado-Laborin","year":"2012","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"11","key":"10.1002\/14651858.CD012836.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.ebiom.2015.10.014","article-title":"Linezolid for treating tuberculosis: a delicate balancing act","volume":"2","author":"Maartens","year":"2015","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1002\/14651858.CD012836.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijmyco.2012.07.001","article-title":"Multidrug and extensively drug-resistant tuberculosis in Lisbon and Vale do Tejo, Portugal, from 2008 to 2010","volume":"1","author":"Macedo","year":"2012","journal-title":"International Journal of Mycobacteriology"},{"issue":"7","key":"10.1002\/14651858.CD012836.pub2-BIB0068|cit68","first-page":"335","article-title":"Treatment of tuberculosis in South Kazakhstan: clinical and economical aspects","volume":"49","author":"Maimakov","year":"2013","journal-title":"Medicina (Kaunas, Lithuania)"},{"issue":"4","key":"10.1002\/14651858.CD012836.pub2-BIB0069|cit69","first-page":"297","article-title":"Increasing pathomorphism of pulmonary tuberculosis: an observational study of slow clinical, microbiological and imaging response of lung tuberculosis to specific treatment. Which role for linezolid?","volume":"13","author":"Manfredi","year":"2009","journal-title":"Brazilian Journal of Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD012836.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijmyco.2015.03.005","article-title":"Factors associated with treatment success and death in cases with multidrug-resistant tuberculosis in Bulgaria, 2009-2010","volume":"4","author":"Milanov","year":"2015","journal-title":"International Journal of Mycobacteriology"},{"issue":"6","key":"10.1002\/14651858.CD012836.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijid.2004.09.012","article-title":"Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran","volume":"9","author":"Mirsaeidi","year":"2005","journal-title":"International Journal of Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD012836.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"e0118919","DOI":"10.1371\/journal.pone.0118919","article-title":"Loss from treatment for drug resistant tuberculosis: risk factors and patient outcomes in a community-based program in Khayelitsha, South Africa","volume":"10","author":"Moyo","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijantimicag.2008.06.014","article-title":"Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis","volume":"33","author":"Nam","year":"2009","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"8","key":"10.1002\/14651858.CD012836.pub2-BIB0074|cit74","first-page":"601","article-title":"The analysis of clinical data about the treatment of linezolid against tuberculosis","volume":"36","author":"Nie","year":"2013","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"issue":"3","key":"10.1002\/14651858.CD012836.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3201\/eid1903.120998","article-title":"Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection","volume":"19","author":"O'Donnell","year":"2013","journal-title":"Emerging Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD012836.pub2-BIB0076|cit76","first-page":"778","article-title":"Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina","volume":"8","author":"Palmero","year":"2004","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"5","key":"10.1002\/14651858.CD012836.pub2-BIB0077|cit77","first-page":"427","article-title":"Adverse drug reactions in multidrug-resistant tuberculosis","volume":"70","author":"Palmero","year":"2010","journal-title":"Medicina"},{"issue":"10","key":"10.1002\/14651858.CD012836.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.arbr.2015.07.003","article-title":"First series of patients with XDR and pre-XDR TB treated with regimens that included meropenen-clavulanate in Argentina","volume":"51","author":"Palmero","year":"2015","journal-title":"Archivos de Bronconeumologia"},{"issue":"3","key":"10.1002\/14651858.CD012836.pub2-BIB0079|cit79","first-page":"361","article-title":"Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea","volume":"8","author":"Park","year":"2004","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"3","key":"10.1002\/14651858.CD012836.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jac\/dkl298","article-title":"Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis","volume":"58","author":"Park","year":"2006","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD012836.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4046\/trd.2010.69.2.95","article-title":"Treatment outcomes and prognostic factors in patients with multidrug-resistant tuberculosis in Korean private hospitals","volume":"69","author":"Park","year":"2010","journal-title":"Tuberculosis and Respiratory Diseases"},{"issue":"5","key":"10.1002\/14651858.CD012836.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"645","DOI":"10.5588\/ijtld.11.0618","article-title":"Trends and challenges in tuberculosis in a medium-sized southern European setting","volume":"16","author":"Pasticci","year":"2012","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"22","key":"10.1002\/14651858.CD012836.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"E806","DOI":"10.1097\/BRS.0b013e3181af7797","article-title":"Multidrug-resistant tuberculosis of the spine-is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients","volume":"34","author":"Pawar","year":"2009","journal-title":"Spine"},{"issue":"9924","key":"10.1002\/14651858.CD012836.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0140-6736(13)62675-6","article-title":"Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study","volume":"383","author":"Pietersen","year":"2014","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4103\/ijmy.ijmy_59_17","article-title":"Treatment outcome of patients having extensively drug-resistant tuberculosis in Gujarat, India","volume":"6","author":"Prajapati","year":"2017","journal-title":"International Journal of Mycobacteriology"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0086|cit86","first-page":"4398","article-title":"Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM)","volume":"38","author":"Ralli","year":"2011","journal-title":"European Respiratory Journal"},{"issue":"10","key":"10.1002\/14651858.CD012836.pub2-BIB0087|cit87","first-page":"1273","article-title":"Outcomes of MDR\/XDR-TB patients treated with linezolid: experience in Thailand","volume":"96","author":"Roongruangpitayakul","year":"2013","journal-title":"Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]"},{"issue":"12","key":"10.1002\/14651858.CD012836.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.5588\/ijtld.12.0322","article-title":"Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children","volume":"16","author":"Rose","year":"2012","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1086\/648675","article-title":"Linezolid in the treatment of multidrug-resistant tuberculosis","volume":"50","author":"Schecter","year":"2010","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD012836.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/cid\/cir772","article-title":"Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome","volume":"54","author":"Seddon","year":"2012","journal-title":"Clinical Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD012836.pub2-BIB0091|cit91","first-page":"977","article-title":"Partial extensively drug resistance (XDR) tuberculosis in children","volume":"48","author":"Shah","year":"2011","journal-title":"Indian Pediatrics"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0092|cit92","doi-asserted-by":"crossref","unstructured":"Singla R Caminero JA Jaiswal A Singla N Gupta S Bali RK Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India European Respiratory Journal 2012 956 62","DOI":"10.1183\/09031936.00076811"},{"issue":"49","key":"10.1002\/14651858.CD012836.pub2-BIB0093|cit93","first-page":"2462","article-title":"Linezolid, an agent from a new class of antibiotics (multiple letters)","volume":"148","author":"Slebos","year":"2004","journal-title":"Nederlands Tijdschrift voor Geneeskunde"},{"issue":"11-12","key":"10.1002\/14651858.CD012836.pub2-BIB0094|cit94","first-page":"25","article-title":"Rezonizat and cycloserine in complex therapy of drug resistant tuberculosis (comparative studies)","volume":"53","author":"Sokolova","year":"2008","journal-title":"Antibiotiki i Khimioterapiia [Antibiotics and Chemoterapy]"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1183\/09031936.00135014","article-title":"Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains","volume":"45","author":"Sotgiu","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0096|cit96","first-page":"Np","article-title":"Multi-drug resistant TB treatment regimen, including bedaquiline and linezolid, failed to reduce transmission over 14 days","volume":"195","author":"Stoltz","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/mdr.2009.0073","article-title":"Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran","volume":"16","author":"Tabarsi","year":"2010","journal-title":"Microbial Drug Resistance (Larchmont, N.Y.)"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0098|cit98","first-page":"A1834","article-title":"Efficacy and safety of linezolid for the treatment of extensively drug resistant tuberculosis","volume":"183","author":"Tang","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0099|cit99","first-page":"33","article-title":"Clinical efficacy and safety of linezolid for the treatment of extensively drug-resistant tuberculosis","volume":"18","author":"Tang","year":"2012","journal-title":"Clinical Microbiology and Infection"},{"issue":"6","key":"10.1002\/14651858.CD012836.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"509","DOI":"10.7883\/yoken.64.509","article-title":"Efficacy and safety of linezolid in the treatment of extensively drug-resistant tuberculosis","volume":"64","author":"Tangg","year":"2011","journal-title":"Japanese Journal of Infectious Diseases"},{"issue":"9","key":"10.1002\/14651858.CD012836.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/cid\/ciw088","article-title":"Effectiveness and safety of imipenem-clavulanate added to an optimized background regimen (OBR) versus OBR control regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"62","author":"Tiberi","year":"2016","journal-title":"Clinical Infectious Diseases"},{"issue":"8","key":"10.1002\/14651858.CD012836.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/j.1469-0691.2009.03063.x","article-title":"Infection due to a novel mycobacterium, mimicking multidrug-resistant Mycobacterium tuberculosis","volume":"16","author":"Tortoli","year":"2010","journal-title":"Clinical Microbiology and Infection"},{"issue":"3","key":"10.1002\/14651858.CD012836.pub2-BIB0103|cit103","first-page":"e50","article-title":"Assessment of linezolid efficacy, safety and tolerability in the treatment of tuberculosis: a retrospective case review","volume":"24","author":"Tse-Chang","year":"2013","journal-title":"Canadian Journal of Infectious Diseases & Medical Microbiology [Journal Canadien des Maladies Infectieuses et de la Microbiologie Medicale]"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1601699","DOI":"10.1183\/13993003.01699-2016","article-title":"Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India","volume":"49","author":"Udwadia","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD012836.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"e58817","DOI":"10.1371\/journal.pone.0058817","article-title":"Serious treatment related adverse drug reactions amongst anti-retroviral naive MDR-TB patients","volume":"8","author":"Walt","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1002\/14651858.CD012836.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2143\/ACB.3269","article-title":"Epidemiology of MDR-TB in a Belgian infectious diseases unit: a 15 years review","volume":"68","author":"Heurck","year":"2013","journal-title":"Acta Clinica Belgica"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/cid\/ciu209","article-title":"Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death","volume":"59","author":"Velasquez","year":"2014","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD012836.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jinf.2005.04.007","article-title":"Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases","volume":"52","author":"Lippe","year":"2006","journal-title":"Journal of Infection"},{"issue":"2","key":"10.1002\/14651858.CD012836.pub2-BIB0109|cit109","first-page":"164","article-title":"Treatment outcome of multidrug-resistant tuberculosis among Vietnamese immigrants","volume":"9","author":"Ward","year":"2005","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12913-017-2118-2","article-title":"Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany","volume":"17","author":"Wirth","year":"2017","journal-title":"BMC Health Services Research"},{"issue":"3","key":"10.1002\/14651858.CD012836.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"358","DOI":"10.5588\/ijtld.11.0493","article-title":"Linezolid in the treatment of MDR-TB: a retrospective clinical study","volume":"16","author":"Xu","year":"2012","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"11","key":"10.1002\/14651858.CD012836.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1469-0691.2011.03716.x","article-title":"Clofazimine in the treatment of multidrug-resistant tuberculosis","volume":"18","author":"Xu","year":"2012","journal-title":"Clinical Microbiology and Infection"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0113|cit113","first-page":"80","article-title":"Clinical efficacy and safety of linezolid for the treatment of extensively drug resistant tuberculosis","volume":"16","author":"Yao","year":"2011","journal-title":"Respirology"},{"issue":"3","key":"10.1002\/14651858.CD012836.pub2-BIB0114|cit114","first-page":"345","article-title":"Linezolid in the treatment of \u2018difficult' multidrug-resistant tuberculosis","volume":"12","author":"Yew","year":"2008","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"6","key":"10.1002\/14651858.CD012836.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1183\/09031936.00111009","article-title":"What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis?","volume":"34","author":"Yew","year":"2009","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD012836.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"631","DOI":"10.5588\/ijtld.14.0191","article-title":"Linezolid in the treatment of drug-resistant tuberculosis: the way forward?","volume":"18","author":"Yew","year":"2014","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"96","DOI":"10.7883\/yoken.JJID.2015.629","article-title":"Linezolid as a potentially effective drug for the treatment of multidrug-resistant tuberculosis in Japan","volume":"70","author":"Yi","year":"2017","journal-title":"Japanese Journal of Infectious Diseases"},{"issue":"4 Supplement","key":"10.1002\/14651858.CD012836.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"176S","DOI":"10.1378\/chest.128.4_MeetingAbstracts.176S","article-title":"Clinical efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis","volume":"128","author":"Agarwal","year":"2005","journal-title":"Chest"},{"issue":"Suppl 51","key":"10.1002\/14651858.CD012836.pub2-BIB0119|cit119","first-page":"454s [2683]","article-title":"Clinical efficacy of once a day linezolid and azithromycin in the treatment of multi drug resistant tuberculosis","volume":"30","author":"Agarwal","year":"2007","journal-title":"European Respiratory Journal"},{"issue":"40","key":"10.1002\/14651858.CD012836.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"20601","DOI":"10.2807\/1560-7917.ES2013.18.40.20601","article-title":"Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007","volume":"18","author":"Anderson","year":"2013","journal-title":"Eurosurveillance"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jinf.2016.12.005","article-title":"Drug resistant TB: UK multicentre study (DRUMS): treatment, management and outcomes in London and West Midlands 2008-2014","volume":"3","author":"Arnold","year":"2017","journal-title":"Infection"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"A3090","DOI":"10.1164\/ajrccm-conference.2017.B27","article-title":"Bedaquiline and linezolid for the operational treatment of multidrug-resistant and extensively drug-resistant tuberculosis in a high burden HIV setting (blix study)","volume":"195","author":"Bionghi","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"1700387","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and safety of bedaquiline containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","volume":"49","author":"Borisov","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD012836.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"472.e7","DOI":"10.1016\/j.cmi.2014.12.022","article-title":"Management of emerging multidrug-resistant tuberculosis in a low-prevalence setting","volume":"21","author":"Catho","year":"2015","journal-title":"Clinical Microbiology and Infection"},{"issue":"14 Supplement","key":"10.1002\/14651858.CD012836.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"P6.319","DOI":"10.1212\/WNL.84.14_supplement.P6.319","article-title":"Linezolid in children with drug resistant tuberculosis and associated peripheral neuropathy","volume":"84","author":"Dey","year":"2015","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"A2114","DOI":"10.1164\/ajrccm-conference.2017.A62","article-title":"Clinical profiles of linezolid resistant tuberculosis cases in Mumbai","volume":"195","author":"Ganatra","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012836.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"ofv175","DOI":"10.1093\/ofid\/ofv175","article-title":"Linezolid in the starter combination for multidrug-resistant tuberculosis: time to move on to group four?","volume":"2","author":"Grard","year":"2015","journal-title":"Open Forum Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD012836.pub2-BIB0128|cit128","first-page":"594","article-title":"Survival and predictors of outcomes in non-HIV-infected patients with extensively drug-resistant tuberculosis","volume":"13","author":"Jeon","year":"2009","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"10","key":"10.1002\/14651858.CD012836.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1086\/522537","article-title":"Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis","volume":"45","author":"Kim","year":"2007","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD012836.pub2-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"1702467","DOI":"10.1183\/13993003.02467-2017","article-title":"Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea","volume":"51","author":"Kim","year":"2018","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"1701105","DOI":"10.1183\/13993003.01105-2017","article-title":"Final treatment outcomes of multidrug and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens","volume":"50","author":"Kuksa","year":"2017","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ijid.2017.10.013","article-title":"Treatment outcomes of rifabutin-containing regimens for rifabutin-sensitive multidrug-resistant pulmonary tuberculosis","volume":"65","author":"Lee","year":"2017","journal-title":"International Journal of Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD012836.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/thoraxjnl-2015-207374","article-title":"Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia - an observational cohort study","volume":"70","author":"Meressa","year":"2015","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jinf.2017.08.005","article-title":"Prevalence and treatment outcome of extensively drug-resistant tuberculosis plus additional drug resistance from the National Clinical Center for Tuberculosis in China: a five-year review","volume":"75","author":"Pang","year":"2017","journal-title":"Journal of Infection"},{"issue":"2","key":"10.1002\/14651858.CD012836.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eimc.2015.04.003","article-title":"Retrospective study of tolerability and efficacy of linezolid in patients with multidrug-resistant tuberculosis (1998-2014)","volume":"34","author":"Ramirez-Lapausa","year":"2016","journal-title":"Enfermedades Infecciosas y Microbiologia Clinica"},{"issue":"7","key":"10.1002\/14651858.CD012836.pub2-BIB0136|cit136","first-page":"567","article-title":"Successful management of highly drug resistant tuberculosis with individualised drug susceptibility testing","volume":"62","author":"Soman","year":"2014","journal-title":"Journal of the Association of Physicians of India"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD012836.pub2-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"PA3486","DOI":"10.1183\/1393003.congress-2017.PA3486","article-title":"Linezolid experience among MDR-TB patients in Mumbai","volume":"50","author":"Tornheim","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD012836.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"336","DOI":"10.4103\/0970-2113.142101","article-title":"Multidrug-resistant-tuberculosis treatment in the Indian private sector: results from a tertiary referral private hospital in Mumbai","volume":"31","author":"Udwadia","year":"2014","journal-title":"Lung India"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0139|cit139","unstructured":"NCT02333799 A phase 3 study assessing the safety and efficacy of bedaquiline plus PA-824 plus linezolid in subjects with drug resistant pulmonary tuberculosis clinicaltrials.gov\/ct2\/show\/NCT02333799"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0140|cit140","unstructured":"NCT02454205 An open-label RCT to evaluate a new treatment regimen for patients with multi-drug resistant tuberculosis (NEXT) clinicaltrials.gov\/ct2\/show\/NCT02454205"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0141|cit141","unstructured":"NCT02589782 Pragmatic clinical trial for a more effective concise and less toxic MDR-TB treatment regimen(s) (TB-PRACTECAL) clinicaltrials.gov\/ct2\/show\/NCT02589782"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0142|cit142","unstructured":"NCT02619994 Treatment shortening of MDR-TB using existing and new drugs (MDR-END) clinicaltrials.gov\/ct2\/show\/NCT02619994"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0143|cit143","unstructured":"NCT02754765 Evaluating newly approved drugs for multidrug-resistant TB (endTB) clinicaltrials.gov\/ct2\/show\/NCT02754765"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0144|cit144","unstructured":"NCT03237182 The individualized M(X) drug-resistant TB treatment strategy study (InDEX) clinicaltrials.gov\/ct2\/show\/NCT03237182"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multi-drug resistant tuberculosis: an individual patient data meta-analysis","volume":"362","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012836.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1183\/13993003.00432-2015","article-title":"Classification of antituberculosis drugs: a new proposal based on the most recent evidence","volume":"46","author":"Caminero","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1440-1843.2012.02257.x","article-title":"Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012","volume":"18","author":"Chang","year":"2013","journal-title":"Respirology"},{"issue":"7","key":"10.1002\/14651858.CD012836.pub2-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1128\/AAC.00388-13","article-title":"Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?","volume":"57","author":"Chang","year":"2013","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"9","key":"10.1002\/14651858.CD012836.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"4097-104","DOI":"10.1128\/AAC.00120-13","article-title":"WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis","volume":"57","author":"Chang","year":"2013","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD012836.pub2-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"447","DOI":"10.5588\/ijtld.11.0451","article-title":"Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"16","author":"Cox","year":"2012","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"8","key":"10.1002\/14651858.CD012836.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/501356","article-title":"Linezolid-induced inhibition of mitochondrial protein synthesis","volume":"42","author":"Vriese","year":"2006","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0152|cit152","unstructured":"Deeks JJ Higgins JP Altman DG (editors) on behalf of the Cochrane Statistical Methods Group Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD012836.pub2-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"iv7","DOI":"10.1093\/jac\/dkr072","article-title":"Linezolid pharmacokinetics and pharmacodynamics in clinical treatment","volume":"66","author":"Dryden","year":"2011","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ijantimicag.2005.03.006","article-title":"In vitro activity of linezolid against multidrug-resistant Mycobacterium tuberculosis isolates","volume":"26","author":"Erturan","year":"2005","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1600993","DOI":"10.1183\/13993003.00993-2016","article-title":"Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis","volume":"49","author":"Fox","year":"2017","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0156|cit156","unstructured":"GRADE Working Group, McMaster University GRADEpro GDT 2015"},{"issue":"12","key":"10.1002\/14651858.CD012836.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","article-title":"GRADE guidelines: 9. Rating up the quality of evidence","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0160|cit160","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD012836.pub2-BIB0161|cit161","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1128\/AAC.00414-07","article-title":"In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years","volume":"52","author":"Huang","year":"2008","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"7303","key":"10.1002\/14651858.CD012836.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0163|cit163","unstructured":"Loke YK Price D Herxheimer A Chapter 14: Adverse effects. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD012836.pub2-BIB0164|cit164","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1753-6561-9-S8-S1","article-title":"Issues in design and interpretation of MDR-TB clinical trials: report of the first Global MDR-TB Clinical Trials Landscape Meeting","volume":"9","author":"Mitnick","year":"2015","journal-title":"BMC Proceedings"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement","volume":"7","author":"Moher","journal-title":"PLoS Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012836.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40264-015-0267-y","article-title":"Safety and tolerability profile of second-line anti-tuberculosis medications","volume":"38","author":"Ramachandran","year":"2015","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0167|cit167","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"1","key":"10.1002\/14651858.CD012836.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0012-3692(15)50981-1","article-title":"Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control","volume":"130","author":"Sharma","year":"2006","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD012836.pub2-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/trstmh\/trv107","article-title":"Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings","volume":"110","author":"Sloan","year":"2016","journal-title":"Transactions of the Royal Society of Tropical Medicine and Hygiene"},{"issue":"6","key":"10.1002\/14651858.CD012836.pub2-BIB0170|cit170","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid-containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0171|cit171","unstructured":"Sterne JA Higgins JP Reeves BC Savovi\u0107 J Turner L ROBINS-I development group ROBINS-I: a tool for assessing Risk Of Bias In Non-randomized Studies of Interventions Available from www.riskofbias.info"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0172|cit172","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1186\/1471-2334-13-468","article-title":"Efficacy and safety of thrice weekly DOTS in tuberculosis patients with and without HIV co-infection: an observational study","volume":"13","author":"Vashishtha","year":"2013","journal-title":"BMC Infectious Diseases"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0173|cit173","volume-title":"Global Tuberculosis Control Report","author":"World Health Organization","year":"2009"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0174|cit174","volume-title":"Treatment of Tuberculosis Guidelines","author":"World Health Organization","year":"2010"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0175|cit175","volume-title":"Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update","author":"World Health Organization","year":"2011"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0176|cit176","volume-title":"Definitions and reporting framework for tuberculosis - 2013 revision (updated December 2014)","author":"World Health Organization","year":"2013"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0177|cit177","volume-title":"The End TB Strategy","author":"World Health Organization","year":"2014"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0178|cit178","volume-title":"Global Tuberculosis Report 2015","author":"World Health Organization","year":"2015"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0179|cit179","volume-title":"Use of high burden country lists for TB by WHO in the post-2015 era","author":"World Health Organization","year":"2015"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0180|cit180","volume-title":"WHO Treatment Guidelines for Drug-Resistant Tuberculosis - 2016 update","author":"World Health Organization","year":"2016"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0181|cit181","volume-title":"Global Tuberculosis Report","author":"World Health Organization","year":"2016"},{"key":"10.1002\/14651858.CD012836.pub2-BIB0182|cit182","unstructured":"World Health Organization Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/RR-TB) Available at: www.who.int\/tb\/publications\/2018\/rapid_communications_MDR\/en\/ 2018"},{"issue":"4","key":"10.1002\/14651858.CD012836.pub2-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3978\/j.issn.2072-1439.2015.03.10","article-title":"Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"7","author":"Zhang","year":"2015","journal-title":"Journal of Thoracic Disease"},{"issue":"11","key":"10.1002\/14651858.CD012836.pub2-BIB0184|cit184","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012836","article-title":"Linezolid for drug-resistant tuberculosis","author":"Singh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012836.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T19:31:33Z","timestamp":1721071893000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD012836.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Infectious Diseases Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,3,20]]},"references-count":184,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012836.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,20]]}}}